The most frequently reported general symptoms are fatigue and weakness, which may be a direct result of anti-PD-1/anti-CTLA-4 therapy, but may also be a symptom of endocrinopathy, e.g., hypothyroidism, or even a sign of progression of the underlying disease. Here, PDCD1 is linked to hypothyroidism.